http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-282844-B6

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e43b4ca6b41ce9f54c9a895d474c81a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
filingDate 1993-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b2e3b6abd5f1e6a3ff5a5b5b96d6fe2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a4c670c01d2d22b9c124e61f3c9ea14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0aa4d1999037129977863578010cfe23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edf4d8fe8ccf21edc1458a6d5a30f602
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6c5d11ab3fb464a99cfa382c4f7d148
publicationDate 1997-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CZ-282844-B6
titleOfInvention Cytarabia-ocphosphate hard capsules
abstract Cytarabine ocphosphate hard capsules that are useful as an antileukemic drug for oral administration. By providing cytarabine ocphosphate hard capsules containing (1) cytarabine ocphosphate, (2) a high molecular weight disintegrant compound and (3) an alkaline, pharmaceutical compositions are obtained having excellent disintegration properties and stability. Cytarabine ocphosphate hard capsules are suitable for clinical use
priorityDate 1992-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6253
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419591227
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1061
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414064869
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID516892
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451010993
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11970473
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410697574
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448020525
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21696466
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451829787
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453918403
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11430
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555131
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415732359
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411550719
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644102
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10239
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10340
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453034310
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23696331
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448098817
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14797

Total number of triples: 50.